The past, present, and future of NK cells in hematopoietic cell transplantation and adoptive transfer

Current Topics in Microbiology and Immunology

Volumn 395, Issue , 2016, Pages 225-243

  Cichocki, Frank ^a   Verneris, Michael R ^a   Cooley, Sarah ^a   Bachanova, Veronika ^a   Brunstein, Claudio G ^a   Blazar, Bruce R ^a   Wagner, John ^a   Schlums, Heinrich ^b   Bryceson, Yenan T ^b,c   Weisdorf, Daniel J ^a   Miller, Jeffrey S ^a,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL SURVIVAL; CELL TRANSPLANTATION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; HEMATOPOIETIC CELL; HUMAN; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS REACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY; IMMUNOLOGY; PROCEDURES;

ADOPTIVE TRANSFER; ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL;

EID: 84958554861     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_445     Document Type: Article

References (118)

1. Appelbaum FR, Dahlberg S, Thomas ED et al (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 101(5):581–588.
2. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL (2002) Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296(5571):1323–1326.
3. Ardolino M, Azimi CS, Iannello A et al (2014) Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124(11):4781–4794.
4. Bachanova V, Burns LJ, McKenna DH et al (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59(11):1739–1744.
5. Bachanova V, Cooley S, Defor TE et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123(25):3855–3863.
6. Beck JC, Wagner JE, DeFor TE et al (2010) Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 16(2):215–222.
7. Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ (2009) Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 15(1):54–60.
8. Biron CA, Welsh RM (1982) Blastogenesis of natural killer cells during viral infection in vivo. J Immunol 129(6):2788–2795.
9. Biron CA, Turgiss LR, Welsh RM (1983) Increase in NK cell number and turnover rate during acute viral infection. J Immunol 131(3):1539–1545.
10. Biron CA, Byron KS, Sullivan JL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320(26):1731–1735.
11. Bishara A, De Santis D, Witt CC et al (2004) The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63(3):204–211.
12. Bordignon C, Daley JP, Nakamura I (1985) Hematopoietic histoincompatibility reactions by NK cells in vitro: model for genetic resistance to marrow grafts. Science 230(4732):1398–1401.
13. Bowden RA, Day LM, Amos DE, Meyers JD (1987) Natural cytotoxic activity against cytomegalovirus-infected target cells following marrow transplantation. Transplantation 44 (4):504–508.
14. Braud VM, Allan DS, O’Callaghan CA et al (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391(6669):795–799.
15. Brown MG, Dokun AO, Heusel JW et al (2001) Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292(5518):934–937.
16. Brunstein CG, Wagner JE, Weisdorf DJ et al (2009) Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 113(22):5628–5634.
17. Bukowski JF, Warner JF, Dennert G, Welsh RM (1985) Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med 161(1):40–52.
18. Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20(4):202–213.
19. Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180 (4):1395–1403.
20. Chan SH, Perussia B, Gupta JW et al (1991) Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173(4):869–879.
21. Colonna M, Samaridis J (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268(5209):405–408.
22. Cooley S, Trachtenberg E, Bergemann TL et al (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3):726–732.
23. Cooley S, Weisdorf DJ, Guethlein LA et al (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192(10):4592–4600.
24. Costa-Garcia M, Vera A, Moraru M, Vilches C, Lopez-Botet M, Muntasell A (2015) Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus. J Immunol 194(6):2715–2724.
25. Daley JP, Nakamura I (1984) Natural resistance of lethally irradiated F1 hybrid mice to parental marrow grafts is a function of H-2/Hh-restricted effectors. J Exp Med 159(4):1132–1148.
26. D’Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL (1995) Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol 155(5): 2306–2310.
27. De Baetselier P, Katzav S, Gorelik E, Feldman M, Segal S (1980) Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature 288 (5787):179–181.
28. Deeg HJ, Storb R, Thomas ED et al (1985) Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65(6):1325–1334.
29. Dinsmore R, Kirkpatrick D, Flomenberg N et al (1984) Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood 63(3):649–656.
30. Doherty PC, Knowles BB, Wettstein PJ (1984) Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv Cancer Res 42:1–65.
31. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M (1996) A human killer inhibitory receptor specific for HLA-A1,2. J Immunol 156(9):3098–3101.
32. Dupont E, Huygen K, Schandene L, Vandercruys M, Palfliet K, Wybran J (1984) Depressed natural killer function in transplant recipients: an analysis. Transplant Proc 16(6):1506–1508.
33. Eisenbach L, Segal S, Feldman M (1983) MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int J Cancer 32(1):113–120.
34. Elmaagacli AH, Steckel NK, Koldehoff M et al (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virusversus-leukemia effect in acute myeloid leukemia patients. Blood 118(5):1402–1412.
35. Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80(3):177–188.
36. Field AK, Davies ME, DeWitt C et al (1983) 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A 80 (13):4139–4143.
37. Fischer JC, Ottinger H, Ferencik S et al (2007) Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Iglike receptor. J Immunol 178(6):3918–3923.
38. Foley B, Cooley S, Verneris MR et al (2012a) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119(11):2665–2674.
39. Foley B, Cooley S, Verneris MR et al (2012b) Human cytomegalovirus (CMV)-induced memorylike NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 189(10):5082–5088.
40. Ford CE, Hamerton JL, Barnes DW, Loutit JF (1956) Cytological identification of radiationchimaeras. Nature 177(4506):452–454.
41. Gasteiger G, Hemmers S, Firth MA et al (2013) IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med 210(6):1167–1178.
42. Geller MA, Cooley S, Judson PL et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13(1):98–107.
43. Ghiringhelli F, Menard C, Terme M et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 (8):1075–1085.
44. Grabstein KH, Eisenman J, Shanebeck K et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264(5161):965–968.
45. Green ML, Leisenring WM, Xie H et al (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324.
46. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155(6):1823–1841.
47. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104(12): 3664–3671.
48. Guma M, Budt M, Saez A et al (2006) Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107(9):3624–3631.
49. Hercend T, Takvorian T, Nowill A et al (1986) Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 67(3):722–728.
50. Hoffman M, Mittelman A, Dworkin B et al (1989) Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. J Cancer Res Clin Oncol 115(2):175–178.
51. Hokland M, Jacobsen N, Ellegaard J, Hokland P (1988) Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation 45(6):1080–1084.
52. Ito S, Pophali P, Co W et al (2013) CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 48(10):1313–1316.
53. Jacobson LO (1952) Evidence for a humoral factor (or factors) concerned in recovery from radiation injury: a review. Cancer Res 12(5):315–325.
54. Jacobson LO, Simmons EL, Marks EK, Robson MJ, Bethard WF, Gaston EO (1950) The role of the spleen in radiation injury and recovery. J Lab Clin Med 35(5):746–770.
55. Johnson FL, Thomas ED, Clark BS, Chard RL, Hartmann JR, Storb R (1981) A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 305(15):846–851.
56. Jonjic S, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH (1989) Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med 169(4):1199–1212.
57. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319(6055):675–678.
58. Katzav S, De Baetselier P, Tartakovsky B, Feldman M, Segal S (1983) Alterations in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from nonmetastatic to metastatic cells. J Natl Cancer Inst 71(2):317–324.
59. Khakoo SI, Thio CL, Martin MP et al (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685):872–874.
60. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G (1977) Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol 7(9):655–663.
61. Kollman C, Howe CW, Anasetti C et al (2001) Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (7):2043–2051.
62. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391(6668):703–707.
63. Lee J, Zhang T, Hwang I et al (2015) Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals. Immunity 42(3):431–442.
64. Lindsley DL, Odell TT Jr, Tausche FG (1955) Implantation of functional erythropoietic elements following total-body irradiation. Proc Soc Exp Biol Med 90(2):512–515.
65. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL (1994) NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180(2):537–543.
66. Ljunggren HG, Karre K (1985) Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162(6):1745–1759.
67. Ljungman P (1998) Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant 21(Suppl 2):S72–S74.
68. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C (2003) Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102(13):4255–4260.
69. Lo Monaco E, Tremante E, Cerboni C, et al (2011) Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 13(9):822–830.
70. Lonnqvist B, Ringden O, Ljungman P, Wahren B, Gahrton G (1986) Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 63(4):671–679.
71. Lorenz E, Uphoff D, Reid TR, Shelton E (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12(1):197–201.
72. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41(11. Pt 1):4420–4425.
73. Lowe EJ, Turner V, Handgretinger R et al (2003) T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 123(2):323–326.
74. Luetke-Eversloh M, Hammer Q, Durek P et al (2014) Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 10(10):e1004441.
75. Mancusi A, Ruggeri L, Urbani E et al (2015) Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces non-relapse mortality. Blood 125 (20):3173−3182.
76. Marin R, Ruiz-Cabello F, Pedrinaci S et al (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54(11):767–775.
77. Martin MP, Gao X, Lee JH et al (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31(4):429–434.
78. Mathe G, Schwarzenberg L, Amiel JL et al (1967) Immunogenetic and immunological problems of allogeneic haemopoietic radio-chimaeras in man. Scand J Haematol 4(3):193–216.
79. Mathe G, Schwarzenberg L, Halle-Pannenko O, Abuaf N, Pouillart P (1977) Of mice and men in bone marrow transplantation. Transplant Proc 9(1):155–168.
80. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057.
81. Miller JS, Cooley S, Parham P et al (2007) Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109(11):5058–5061.
82. Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453–1464.
83. Moretta A, Vitale M, Bottino C et al (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Antip58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178(2):597–604.
84. Nachbaur D, Bonatti H, Oberaigner W et al (2001) Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 358(9288):1157–1159.
85. Neiman P, Wasserman PB, Wentworth BB et al (1973) Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation 15(5): 478–485.
86. Nguyen S, Dhedin N, Vernant JP et al (2005) NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105(10):4135–4142.
87. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12/ 15/18-preactivated NK cells against established tumors. J Exp Med 209(13):2351–2365.
88. Nowell PC, Cole LJ, Habermeyer JG, Roan PL (1956) Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res 16(3):258–261.
89. Oevermann L, Michaelis SU, Mezger M et al (2014) KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 124(17): 2744–2747.
90. Okamura H, Tsutsi H, Komatsu T et al (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378(6552):88–91.
91. Olcese L, Lang P, Vely F et al (1996) Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J Immunol 156(12):4531–4534.
92. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J (2011) Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34(+) progenitors. J Gen Virol 92(Pt 7):1539–1549.
93. Quinnan GV Jr, Kirmani N, Rook AH et al (1982) Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307(1):7–13.
94. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61(10):3102–3108.
95. Remberger M, Ringden O (2002) Survival after bone-marrow transplantation. Lancet 359 (9309):888.
96. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161(5):1169–1188.
97. Rosenberg SA, Lotze MT, Muul LM et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–897.
98. Ruggeri L, Capanni M, Casucci M et al (1999) Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 94(1):333–339.
99. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100.
100. Schlums H, Cichocki F, Tesi B et al (2015) Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function. Immunity 42 (3):443–456.
101. Selby P, Powles RL, Jameson B, Stolle K, Tryhorn Y, Stern H (1986) Treatment of cytomegalovirus pneumonitis after bone marrow transplantation with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine. Lancet 1(8494):1377–1378.
102. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D (2013) Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med 210(6):1153–1165.
103. Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457 (7229):557–561.
104. Suto Y, Maenaka K, Yabe T et al (1996) Chromosomal localization of the human natural killer cell class I receptor family genes to 19q13.4 by fluorescence in situ hybridization. Genomics 35 (1):270–272.
105. Sylwester AW, Mitchell BL, Edgar JB et al (2005) Broadly targeted human cytomegalovirusspecific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202(5):673–685.
106. Thomas ED, Lochte HL Jr., Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257(11):491–496.
107. Thomson KJ, Mackinnon S, Peggs KS (2012) CMV-specific cellular therapy for acute myeloid leukemia? Blood 119(4):1088–1090; author reply 1090–1081.
108. Tomasec P, Braud VM, Rickards C et al (2000) Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287(5455):1031.
109. Uhrberg M, Valiante NM, Shum BP et al (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7(6):753–763.
110. Ulbrecht M, Martinozzi S, Grzeschik M et al (2000) Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 164(10):5019–5022.
111. Venstrom JM, Pittari G, Gooley TA et al (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367(9):805–816.
112. Wagtmann N, Biassoni R, Cantoni C et al (1995) Molecular clones of the p58. NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2(5):439–449.
113. Weiden PL, Flournoy N, Thomas ED et al (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300(19):1068–1073.
114. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304(25):1529–1533.
115. Welsh RM Jr. (1978) Mouse natural killer cells: induction specificity, and function. J Immunol 121 (5):1631–1635.
116. Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA (2008) The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 84 (4):973–980.
117. Yron I, Wood TA Jr., Spiess PJ, Rosenberg SA (1980) In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125 (1):238–245.
118. Zhang T, Scott JM, Hwang I, Kim S (2013) Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRgamma deficiency. J Immunol 190(4):1402–1406